Get started
DR. LAL PATHLABS LIMITEDDR. LAL PATHLABS LIMITEDDR. LAL PATHLABS LIMITED

DR. LAL PATHLABS LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

LALPATHLAB chart


Full chart

LALPATHLAB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪230.93 B‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
55.30
Basic EPS (TTM)
50.05 INR
Net income (FY)
‪3.58 B‬ INR
Revenue (FY)
‪22.27 B‬ INR
Shares float
‪37.19 M‬
Beta (1Y)
0.65

Employees


Employees (FY)
‪4.1 K‬
Change (1Y)
+51 +1.26%
Revenue / Employee (1Y)
‪5.43 M‬ INR
Net income / Employee (1Y)
‪872.74 K‬ INR

About DR. LAL PATH LABS LTD.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Shankha Banerjee
Website
lalpathlabs.com
Headquarters
Gurgaon
Founded
1949
ISIN
INE600L01024
FIGI
BBG009WQGFB4
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. It also involves in providing diagnostic and healthcare tests and services. The company was founded by S. K. Lal in 1949 and is headquartered in Gurgaon, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LALPATHLAB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as LALPATHLAB.

Frequently Asked Questions


The current price of LALPATHLAB is 2,767.05 INR — it has decreased by −0.31% in the past 24 hours. Watch DR. LAL PATHLABS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange DR. LAL PATHLABS LIMITED stocks are traded under the ticker LALPATHLAB.
LALPATHLAB stock has risen by 0.51% compared to the previous week, the month change is a 10.07% rise, over the last year DR. LAL PATHLABS LIMITED has showed a 21.51% increase.
We've gathered analysts' opinions on DR. LAL PATHLABS LIMITED future price: according to them, LALPATHLAB price has a max estimate of 3,770.00 INR and a min estimate of 2,380.00 INR. Watch LALPATHLAB chart and read a more detailed DR. LAL PATHLABS LIMITED stock forecast: see what analysts think of DR. LAL PATHLABS LIMITED and suggest that you do with its stocks.
LALPATHLAB reached its all-time high on Sep 15, 2021 with the price of 4,243.00 INR, and its all-time low was 696.50 INR and was reached on Jan 20, 2016. View more price dynamics on LALPATHLAB chart.
See other stocks reaching their highest and lowest prices.
LALPATHLAB stock is 3.69% volatile and has beta coefficient of 0.65. Track DR. LAL PATHLABS LIMITED stock price on the chart and check out the list of the most volatile stocks — is DR. LAL PATHLABS LIMITED there?
Today DR. LAL PATHLABS LIMITED has the market capitalization of ‪230.20 B‬, it has increased by 0.33% over the last week.
Yes, you can track DR. LAL PATHLABS LIMITED financials in yearly and quarterly reports right on TradingView.
DR. LAL PATHLABS LIMITED is going to release the next earnings report on Apr 25, 2025. Keep track of upcoming events with our Earnings Calendar.
LALPATHLAB earnings for the last quarter are 11.60 INR per share, whereas the estimation was 11.74 INR resulting in a −1.19% surprise. The estimated earnings for the next quarter are 11.95 INR per share. See more details about DR. LAL PATHLABS LIMITED earnings.
DR. LAL PATHLABS LIMITED revenue for the last quarter amounts to ‪5.97 B‬ INR, despite the estimated figure of ‪5.97 B‬ INR. In the next quarter, revenue is expected to reach ‪6.04 B‬ INR.
LALPATHLAB net income for the last quarter is ‪967.00 M‬ INR, while the quarter before that showed ‪1.29 B‬ INR of net income which accounts for −25.15% change. Track more DR. LAL PATHLABS LIMITED financial stats to get the full picture.
DR. LAL PATHLABS LIMITED dividend yield was 1.06% in 2023, and payout ratio reached 55.76%. The year before the numbers were 0.66% and 41.63% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 23, 2025, the company has ‪4.1 K‬ employees. See our rating of the largest employees — is DR. LAL PATHLABS LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DR. LAL PATHLABS LIMITED EBITDA is ‪6.71 B‬ INR, and current EBITDA margin is 27.83%. See more stats in DR. LAL PATHLABS LIMITED financial statements.
Like other stocks, LALPATHLAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DR. LAL PATHLABS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DR. LAL PATHLABS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DR. LAL PATHLABS LIMITED stock shows the buy signal. See more of DR. LAL PATHLABS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.